BCAL Diagnostics Past Earnings Performance
Past criteria checks 0/6
BCAL Diagnostics's earnings have been declining at an average annual rate of -49.6%, while the Biotechs industry saw earnings growing at 12.8% annually. Revenues have been growing at an average rate of 80.9% per year.
Key information
-49.6%
Earnings growth rate
-38.8%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 80.9% |
| Return on equity | -82.4% |
| Net Margin | -134.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How BCAL Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4 | -5 | 4 | 4 |
| 30 Sep 23 | 3 | -5 | 3 | 4 |
| 30 Jun 23 | 3 | -5 | 3 | 4 |
| 31 Mar 23 | 2 | -5 | 3 | 4 |
| 31 Dec 22 | 1 | -5 | 2 | 3 |
| 30 Sep 22 | 1 | -4 | 2 | 3 |
| 30 Jun 22 | 1 | -3 | 2 | 2 |
| 31 Mar 22 | 1 | -3 | 1 | 2 |
| 31 Dec 21 | 1 | -3 | 1 | 2 |
| 30 Sep 21 | 0 | -2 | 1 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 1 | 0 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 30 Jun 19 | 0 | 0 | 0 | 0 |
| 30 Jun 18 | 0 | 0 | 0 | 0 |
Quality Earnings: BDX is currently unprofitable.
Growing Profit Margin: BDX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BDX is unprofitable, and losses have increased over the past 5 years at a rate of 49.6% per year.
Accelerating Growth: Unable to compare BDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-1%).
Return on Equity
High ROE: BDX has a negative Return on Equity (-82.36%), as it is currently unprofitable.